Patent US4465666A successfully refreshed from Google Patents.
US4465666A
Expired / Lapsed
US
⏱️ 0.0 years remaining
New pharmaceutical preparations
Assignee: Novartis Corp
•
Filing: 1981-10-30
•
Granted: 1984-08-14
•
Expires: 2001-10-30
Abstract
Abstract The invention relates to new pharmaceutical preparations for the topical treatment of infections caused by herpes viruses, especially those which have been caused by herpes virus hominis, for example of herpes genitalis and herpes dermatitis. The preparations contain as antiviral agent a synergistic combination of an acid sulphated polysaccharide or acid sulphated polymer, in particular heparin, and zinc ions, and may further contain polyoxyethylene sorbitan monolaurate and/or -monooleate. They are usual types of preparations for topical administration such as tinctures, solutions, creams, ointments and, especially, gels.
Inventors
- 👤 Bohumir Lukas
- 👤 Walter Wiesendanger
- 👤 Karl H. Schmidt-Ruppin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 10:33
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/24; A61K33/30; A61K47/00; A61K47/06; A61K47/26; A61K9/00; A61K9/0012; A61K9/0014; A61P; A61P31/00; A61P31/12; A61P31/20; A61P31/22
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
69 words
Pharmaceutical preparation for topical administration comprising an anti-viral effective amount of an acid sulfated polysaccharide or acid sulfated polymer selected from the group consisting of heparin, dextran sulfate and polyvinyl sulfate; and zinc ions in the form of a dissociable zinc compound in a weight ratio of acid sulfated polysaccharide or acid sulfated polymer to zinc ions of 1:0.18 to 4.5 together with pharmaceutical adjuvants suitable for topical application.
Claim 2
Dependent Claim
69 words
Pharmaceutical preparation for topical administration comprising an anti-viral effective amount of an acid sulfated polysaccharide or acid sulfated polymer selected from the group consisting of heparin, dextran sulfate and polyvinyl sulfate; and zinc ions in the form of a dissociable zinc compound in a weight ratio of acid sulfated polysaccharide or acid sulfated polymer to zinc ions of 1:0.18 to 4.5 together with pharmaceutical adjuvants suitable for topical application.
Claim 3
Dependent Claim
25 words
Pharmaceutical preparation according to claim 1 wherein the acid sulphated polysaccharide or acid sulphated polymer is present in the form of a pharmaceutically acceptable salt.
Claim 4
Dependent Claim
13 words
Pharmaceutical preparation according to claim 2 wherein the pharmaceutically acceptable salt is heparin.
Claim 5
Dependent Claim
14 words
Pharmaceutical preparation according to claim 2 wherein the pharmaceutically acceptable salt is dextran sulfate.
Claim 6
Dependent Claim
14 words
Pharmaceutical preparation according to claim 2 wherein the pharmaceutically acceptable salt is polyvinyl sulfate.
Claim 7
Dependent Claim
24 words
Pharmaceutical preparation according to claim 1 which additionally contains at least one surface active agent selected from polyoxyethylene sorbitan monolaurate and polyoxyethylene sorbitan monooleate.
Claim 8
Dependent Claim
23 words
Pharmaceutical preparation according to claim 1 which contains heparin and zinc ions in a ratio of 160 IU to 0.18 to 18 mg.
Claim 9
Dependent Claim
33 words
Pharmaceutical preparation according to claim 1 which contains, per gram or milliliter, 0.1 to 5 mg of an acid sulphated polysaccharide or acid sulphated polymer and 0.18 to 18 mg of zinc ions.
Claim 10
Dependent Claim
26 words
Pharmaceutical preparation according to claim 8 which contains, per gram or milliliter, 16 to 800 IU of heparin and 0.18 to 18 mg of zinc ions.
Claim 11
Dependent Claim
26 words
Pharmaceutical preparation according to claim 8 which contains, per gram or milliliter, 40 to 480 IU of heparin and 0.18 to 18 mg of zinc ions.
Claim 12
Dependent Claim
31 words
Pharmaceutical preparation according to claim 10 which additionally contains, per gram or milliliter, 0.5 to 10 mg of a surface active agent selected from polyoxyethylene sorbitan monolaurate and polyoxymethylene sorbitan monooleate.
Claim 13
Dependent Claim
31 words
Pharmaceutical preparation according to claim 8 to which the zinc ions are added in the form of 0.8 to 80 mg of ZnSO 4 .7H 2 O as dissociable zinc compound.
Claim 14
Dependent Claim
22 words
Pharmaceutical preparation according to claim 8 which contains 80 to 320 IU of heparin, and 0.45 to 4.5 mg of zinc ions.
Claim 15
Dependent Claim
31 words
Pharmaceutical preparation according to claim 13 which additionally contains, per gram or milliliter, 0.5 to 10 mg of a surface active agent selected from polyoxyethylene sorbitan monolaurate and polyoxymethylene sorbitan monooleate.
Claim 16
Dependent Claim
31 words
Pharmaceutical preparation according to claim 13 to which the zinc ions are added in the form of 2.0 to 20 mg of ZnSO 4 .7H 2 O as dissociable zinc compound.
Claim 17
Dependent Claim
31 words
Pharmaceutical preparation according to claim 8 which additionally contains, per gram or milliliter, 0.2 to 50 mg of a surface active agent selected from polyoxyethylene sorbitan monolaurate and polyoxyethylene sorbitan monooleate.
Claim 18
Dependent Claim
31 words
Pharmaceutical preparation according to claim 8 which additionally contains, per gram or milliliter, 0.5 to 10 mg of a surface active agent selected from polyoxyethylene sorbitan monolaurate and polyoxyethylene sorbitan monooleate.
Claim 19
Dependent Claim
33 words
Pharmaceutical preparation according to claim 1 which contains, per gram or milliliter, 0.25 to 3 mg of an acid sulphated polysaccharide or acid sulphated polymer and 0.18 to 18 mg of zinc ions.
Claim 20
Dependent Claim
27 words
Pharmaceutical preparation according to claim 1 wherein the dissociable zinc compound is selected from the group consisting of zinc sulfate, zinc chloride, zinc acetate and zinc citrate.
Claim 21
Dependent Claim
44 words
A method for the treatment of infections caused by herpes viruses which comprises the topical administration to the infected part of the body of an animal host in need of such treatment an antivirally effective amount of a pharmaceutical preparation according to claim 1.
Claim 22
Dependent Claim
41 words
A method for the treatment of herpes genitalis which comprises the topical administration to the infected part of the body of an animal host in need of such treatment an antivirally effective amount of a pharmaceutical preparation according to claim 1.
Claim 23
Dependent Claim
41 words
A method for the treatment of herpes dermatitis which comprises the topical administration to the infected part of the body of an animal host in need of such treatment an antivirally effective amount of a pharmaceutical preparation according to claim 1.
References Cited (Backward Citations)
DE2715711A1
Cited
EP0000133A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-08-14 | 1988-02-13 | 1988-08-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-08-14 | 1992-02-13 | 1992-08-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-08-14 | 1996-02-13 | 1996-08-14 | $7700.00 | Window Closed / Lapsed |